Abstracts tagged "Infection"

Abstract Number: 2155 • 2014 ACR/ARHP Annual Meeting
Chikungunya Fever in Patients Under Biologics
Lauren Brunier¹, Katleen Polomat², Christophe Deligny², Veronique Dehlinger³, Patrick Numeric⁴, Georges Jean-Baptiste³, Serge Arfi² and Michel De Bandt⁵, ¹CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ²CHUM de Martinique,, unit of internal medicine, Fort de France, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁴route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ⁵Rheumatology, Hopital Zobda-Quitman. CHU La Meynard., Fort de FRance, France
Background/Purpose Chick is an epidemic disease due to an arthropod-borne virus (Alphavirus) transmitted by Aedes mosquitoes. CHIKV causes an acute illness with a febrile phase,…
Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting
Effectiveness of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Hideyuki Horikoshi¹, Takashi Nakanishi¹, Reiko Takahashi¹, Fumihiko Kimura² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly. It is characterized by pain and stiffness in the shoulder and pelvic girdles. …
Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
Yoichiro Akiyama¹, Takeo Sato¹, Takamasa Murosaki¹, Katsuya Nagatani¹ and Seiji Minota², ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi-Ken, Japan
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…
Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Kenneth G. Saag¹, Kevin L. Winthrop², Daniel E. Furst³, Kimberly Alexander⁴, Angelika Jahreis⁵, Carol Chung⁶ and Kurt Oelke⁷, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³University of California at Los Angeles, Los Angeles, CA, ⁴Epidemiology, Genentech, Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Genentech, Inc, South San Francisco, CA, ⁷Rheumatic Disease Center, Glendale, WI
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Bei-Hung Chang^1,2, Lien Quach¹, Mary Brophy³, Keri Hannagan⁴, Edward C. Keystone⁵, Ted R. Mikuls⁶ and James R. O'Dell⁷, ¹VA Boston Healthcare System, Boston, MA, ²Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ³VA Boston Heathcare System, Boston, MA, ⁴MAVERIC, VA Boston Heathcare System, Boston, MA, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
Abstract Number: 476 • 2014 ACR/ARHP Annual Meeting
Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Lucile Poiroux¹, Yannick Allanore², Andre Kahan³ and Jerome Avouac⁴, ¹Rhumatologie A, Cochin Hospital, Paris, France, ²Rheumatology, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, ³Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁴Cochin Hospital, Paris, France
Background/Purpose: TNF-a inhibitors have changed the prognosis of rheumatoid arthritis (RA). The number of molecules and the time of exposure have increased. However, few studies…
Abstract Number: 473 • 2014 ACR/ARHP Annual Meeting
Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids
Jacques Morel¹, Florence Tubach^2,3, Yannick Allanore⁴, Daniel Wendling⁵, Celine Cozic⁶, Emmanuelle Dernis Labous⁷, Eric Legangneux⁸, Thao Pham⁹, Sophie Odoit¹⁰, Isabelle Roitg¹¹, Isabelle Koné-Paut¹², Pierre Quartier¹³, Jean Sibilia¹⁴ and Severine Guillaume Czitrom¹⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ³INSERM, Universite Paris Diderot, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Rheumatology, CHD la Roche sur Yon, La Roche Sur Yon, France, ⁷Rhumatologie, Ch Du Mans, Le Mans, France, ⁸Rheumatology, Centre Hospitalier Public du Cotentin, 50100, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Dermatology, CHU de la Réunion, Saint Denis, France, ¹¹Hopital De Perpignan, Perpignan, France, ¹²Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁵Ch De Bicetre, Le Kremlin Bicetre Cedex, France
Background/Purpose To assess varicella zona virus (VZV) infection features under biological drugs. Methods A call for observations was sent from april 2013 to april 2014…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…
Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Devy Zisman^1,2, Haim Bitterman^1,3, Ilan Feldhamer⁴, Doron Comanesther⁴, Erez Battat⁴, Sari Greenberg-Dotan⁴, Sarit Cohen⁵ and Arnon-Dov Cohen⁴, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Medical Center, Haifa, Israel
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…
Abstract Number: 2166 • 2013 ACR/ARHP Annual Meeting
Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis
Caroline Y Chang¹, Rika Meyer² and Katherine AB Marzan¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are extremely effective in treating Juvenile Idiopathic Arthritis (JIA). However, TNF-α is critical in immune function, raising concerns of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].